Drug Profile
Elipovimab - Glilead Sciences
Alternative Names: GS-9722Latest Information Update: 16 May 2022
Price :
$50
*
At a glance
- Originator Gilead Sciences
- Class Antibodies; Antivirals; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 28 Apr 2022 Discontinued - Phase-I for HIV infections in USA (Parenteral) (Gilead Sciences pipeline, May 2022)
- 08 Mar 2020 Pharmacokinetics and adverse event data from a phase I trial in HIV-negative patients and in patients with HIV presented at the 27th Conference on Retroviruses and Opportunistic Infections (CROI-2020)
- 13 Jan 2020 Gilead Sciences in-licenses Xtend™ XmAb® Fc Technology and Cytotoxic XmAb® Fc Technology from Xencor.